{"id":16432,"date":"2017-07-27T12:16:59","date_gmt":"2017-07-27T11:16:59","guid":{"rendered":"https:\/\/faus-moliner.com\/en\/la-autorizacion-global-comprende-todas-las-innovaciones-ulteriores-del-medicamento\/"},"modified":"2017-09-05T14:25:51","modified_gmt":"2017-09-05T13:25:51","slug":"the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product","status":"publish","type":"post","link":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/","title":{"rendered":"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product"},"content":{"rendered":"

Background<\/strong><\/p>\n

In 2001, Novartis obtained a marketing authorization under a centralised procedure for the medicinal product Zometa\u00ae, the active substance of which is zoledronic acid and which is indicated to treat certain bone complications in patients with cancer. In 2005, Novartis obtained another marketing authorization under a centralised procedure for the medicinal product Aclasta\u00ae, which has the same active substance but its therapeutic indications are not oncological and its dosage is different from the one of Zometa\u00ae. In 2011, Teva and Hospira both submitted MA applications for their respective generic medicinal products, with zoledronic acid as active substance and using Aclasta\u00ae as a reference medicinal product. In 2012, the European Commission (EC) granted such marketing authorizations, with indications and dosages both of Aclasta\u00ae as well as Zometa\u00ae.<\/p>\n

In 2012, Novartis appealed the granting of such MAs before the General Court of the EU alleging that the data protection period of Aclasta\u00ae which, in its opinion, was different from the one of Zometa\u00ae, had not been respected. In 2015, the General Court rejected the appeals of Novartis ruling that Aclasta\u00ae and Zometa\u00ae were included in the same \u201cglobal marketing authorisation\u201d. This judgement of the Court of Justice of the European Union (CJEU) decides on the appeals of Novartis against the previous judgements of the General Court.<\/p>\n

Position of the CJEU<\/strong><\/p>\n

In its judgement, the CJEU rejects the appeals of Novartis and values the interpretation of the concept of \u201cglobal marketing authorisation\u201d on the basis of the same principles that inspired the Generics case of 1998: when a medicinal product obtains an initial marketing authorization, any strength, pharmaceutical form, administration route and additional presentation, as well as any variations and extensions that are authorised will be considered as included in the same global marketing authorisation and there will not be an independent data protection period.<\/p>\n

The CJEU relies on the fact that Directive 2001\/83 makes no distinction between developments authorised through the grant of a separate marketing authorization and developments of the original medicinal product authorised through a variation of the initial marketing authorization. Accordingly, the CJEU states that the concept of \u201cglobal marketing authorisation\u201d covers all subsequent developments of the original medicinal product, irrespective of their authorisation procedures, namely through the variation of the initial marketing authorization for that medicinal product or through the grant of a separate marketing authorization.<\/p>\n","protected":false},"excerpt":{"rendered":"

Background In 2001, Novartis obtained a marketing authorization under a centralised procedure for the medicinal product Zometa\u00ae, the active substance of which is zoledronic acid and which is indicated to treat certain bone complications in patients with cancer. In 2005, Novartis obtained another marketing authorization under a centralised procedure for the medicinal product Aclasta\u00ae, which… <\/p>\n

<\/div>\n

Read More<\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[72,86,217],"tags":[],"coauthors":[],"class_list":["post-16432","post","type-post","status-publish","format-standard","hentry","category-capsulas-en","category-pharmaceutical-and-life-sciences-law","category-pharmaceutical-and-life-sciences-law-2"],"acf":[],"yoast_head":"\nThe \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product - Faus Moliner<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product - Faus Moliner\" \/>\n<meta property=\"og:description\" content=\"Background In 2001, Novartis obtained a marketing authorization under a centralised procedure for the medicinal product Zometa\u00ae, the active substance of which is zoledronic acid and which is indicated to treat certain bone complications in patients with cancer. In 2005, Novartis obtained another marketing authorization under a centralised procedure for the medicinal product Aclasta\u00ae, which... Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\" \/>\n<meta property=\"og:site_name\" content=\"Faus Moliner\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-27T11:16:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-09-05T13:25:51+00:00\" \/>\n<meta name=\"author\" content=\"Ver\u00f3nica Car\u00edas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ver\u00f3nica Car\u00edas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\"},\"author\":{\"name\":\"Ver\u00f3nica Car\u00edas\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/dd68e852bc64e943d0431ad028cbe2e2\"},\"headline\":\"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product\",\"datePublished\":\"2017-07-27T11:16:59+00:00\",\"dateModified\":\"2017-09-05T13:25:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\"},\"wordCount\":393,\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"articleSection\":[\"Capsulas\",\"Pharmaceutical and Life Sciences Law\",\"Pharmaceutical and Life Sciences Law\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\",\"url\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\",\"name\":\"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product - Faus Moliner\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\"},\"datePublished\":\"2017-07-27T11:16:59+00:00\",\"dateModified\":\"2017-09-05T13:25:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/faus-moliner.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"name\":\"faus-moliner.com\",\"description\":\"Otro sitio realizado con WordPress\",\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/faus-moliner.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\",\"name\":\"Faus Moliner\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"contentUrl\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"width\":400,\"height\":283,\"caption\":\"Faus Moliner\"},\"image\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/2372042\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/dd68e852bc64e943d0431ad028cbe2e2\",\"name\":\"Ver\u00f3nica Car\u00edas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/cc93b8aa45fd968b515d32b18e546f63\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27ba446bf972706cf2fbbcb7e25744c25172a381f0a5232b0811cf294662bddd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27ba446bf972706cf2fbbcb7e25744c25172a381f0a5232b0811cf294662bddd?s=96&d=mm&r=g\",\"caption\":\"Ver\u00f3nica Car\u00edas\"},\"sameAs\":[\"https:\/\/faus-moliner.com\/\"],\"url\":\"https:\/\/faus-moliner.com\/en\/author\/veronica-carias\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product - Faus Moliner","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/","og_locale":"en_US","og_type":"article","og_title":"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product - Faus Moliner","og_description":"Background In 2001, Novartis obtained a marketing authorization under a centralised procedure for the medicinal product Zometa\u00ae, the active substance of which is zoledronic acid and which is indicated to treat certain bone complications in patients with cancer. In 2005, Novartis obtained another marketing authorization under a centralised procedure for the medicinal product Aclasta\u00ae, which... Read More","og_url":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/","og_site_name":"Faus Moliner","article_published_time":"2017-07-27T11:16:59+00:00","article_modified_time":"2017-09-05T13:25:51+00:00","author":"Ver\u00f3nica Car\u00edas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ver\u00f3nica Car\u00edas","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/#article","isPartOf":{"@id":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/"},"author":{"name":"Ver\u00f3nica Car\u00edas","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/dd68e852bc64e943d0431ad028cbe2e2"},"headline":"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product","datePublished":"2017-07-27T11:16:59+00:00","dateModified":"2017-09-05T13:25:51+00:00","mainEntityOfPage":{"@id":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/"},"wordCount":393,"publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"articleSection":["Capsulas","Pharmaceutical and Life Sciences Law","Pharmaceutical and Life Sciences Law"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/","url":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/","name":"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product - Faus Moliner","isPartOf":{"@id":"https:\/\/faus-moliner.com\/en\/#website"},"datePublished":"2017-07-27T11:16:59+00:00","dateModified":"2017-09-05T13:25:51+00:00","breadcrumb":{"@id":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/faus-moliner.com\/en\/the-global-marketing-authorisation-covers-all-subsequent-developments-of-the-medicinal-product\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/faus-moliner.com\/en\/"},{"@type":"ListItem","position":2,"name":"The \u201cglobal marketing authorisation\u201d covers all subsequent developments of the medicinal product"}]},{"@type":"WebSite","@id":"https:\/\/faus-moliner.com\/en\/#website","url":"https:\/\/faus-moliner.com\/en\/","name":"faus-moliner.com","description":"Otro sitio realizado con WordPress","publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/faus-moliner.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/faus-moliner.com\/en\/#organization","name":"Faus Moliner","url":"https:\/\/faus-moliner.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","contentUrl":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","width":400,"height":283,"caption":"Faus Moliner"},"image":{"@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/2372042\/admin\/"]},{"@type":"Person","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/dd68e852bc64e943d0431ad028cbe2e2","name":"Ver\u00f3nica Car\u00edas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/cc93b8aa45fd968b515d32b18e546f63","url":"https:\/\/secure.gravatar.com\/avatar\/27ba446bf972706cf2fbbcb7e25744c25172a381f0a5232b0811cf294662bddd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27ba446bf972706cf2fbbcb7e25744c25172a381f0a5232b0811cf294662bddd?s=96&d=mm&r=g","caption":"Ver\u00f3nica Car\u00edas"},"sameAs":["https:\/\/faus-moliner.com\/"],"url":"https:\/\/faus-moliner.com\/en\/author\/veronica-carias\/"}]}},"_links":{"self":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/posts\/16432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/comments?post=16432"}],"version-history":[{"count":0,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/posts\/16432\/revisions"}],"wp:attachment":[{"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/media?parent=16432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/categories?post=16432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/tags?post=16432"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/faus-moliner.com\/en\/wp-json\/wp\/v2\/coauthors?post=16432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}